A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

This study is creating a large pan-Asian database of clinical information on patients with a specific type of lung cancer called EGFR Exon 20 insertion-mutated NSCLC (non-small cell lung cancer). This rare mutation is harder to treat with standard EGFR drugs, and this registry aims to improve understanding of real-world treatment patterns and outcomes across Asia. **You may be eligible if...** - You have been diagnosed with advanced NSCLC confirmed by biopsy - Your tumor has been tested and found to have an EGFR Exon 20 insertion mutation - You were diagnosed between January 1, 2013 and December 31, 2024 - You are an adult (age requirements follow local regulations) **You may NOT be eligible if...** - Your tumor does not have an EGFR Exon 20 insertion mutation Talk to your doctor to see if this trial is right for you.